| 1.15 0.09 (8.49%) | 12-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.5 | 1-year : | 1.76 |
| Resists | First : | 1.28 | Second : | 1.5 |
| Pivot price | 1.1 |
|||
| Supports | First : | 0.92 | Second : | 0.76 |
| MAs | MA(5) : | 1.1 |
MA(20) : | 1.13  |
| MA(100) : | 1.44 |
MA(250) : | 2.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 56.5 |
D(3) : | 51 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 3.78 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LXRX ] has closed below upper band by 21.0%. Bollinger Bands are 62.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.16 - 1.17 | 1.17 - 1.18 |
| Low: | 1.03 - 1.03 | 1.03 - 1.04 |
| Close: | 1.14 - 1.15 | 1.15 - 1.16 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Thu, 30 Nov 2023
Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 ... - Yahoo Finance
Wed, 22 Nov 2023
Lexicon Pharmaceuticals to Participate in the 35th Annual Piper ... - Yahoo Finance
Wed, 22 Nov 2023
How Will the Market React to Lexicon Pharmaceuticals Inc (LXRX) Stock Getting a Bearish Rating - InvestorsObserver
Wed, 15 Nov 2023
Lexicon Pharmaceuticals Inc (LXRX) is up 2.68% Wednesday In Premarket Trading - InvestorsObserver
Tue, 14 Nov 2023
Insiders Buying Blend Labs And 3 Other Stocks Under $2 By Benzinga - Investing.com UK
Tue, 14 Nov 2023
Director Philippe Amouyal's Strategic 200,000 Share Purchase in ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 245 (M) |
| Held by Insiders | 1.036e+008 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 20,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.5478e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -30 % |
| Return on Assets (ttm) | 636.4 % |
| Return on Equity (ttm) | -41.5 % |
| Qtrly Rev. Growth | 530000 % |
| Gross Profit (p.s.) | 271.89 |
| Sales Per Share | -96 |
| EBITDA (p.s.) | -4.54138e+007 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -133 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 2.34 |
| Dividend | 0 |
| Forward Dividend | 2.198e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|